ArrowMark Colorado Holdings LLC bought a new position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 160,899 shares of the company's stock, valued at approximately $2,478,000. ArrowMark Colorado Holdings LLC owned 1.11% of Inhibrx at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. acquired a new position in shares of Inhibrx in the 4th quarter worth approximately $28,000. Natixis acquired a new stake in shares of Inhibrx during the fourth quarter valued at approximately $31,000. JPMorgan Chase & Co. lifted its position in shares of Inhibrx by 47.8% in the 4th quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock valued at $117,000 after acquiring an additional 2,457 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Inhibrx during the 4th quarter worth approximately $47,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Inhibrx in the fourth quarter valued at $53,000. Institutional investors own 82.46% of the company's stock.
Inhibrx Stock Up 2.0 %
Shares of Inhibrx stock traded up $0.22 during trading on Friday, hitting $11.48. 35,029 shares of the stock traded hands, compared to its average volume of 105,284. The company has a fifty day moving average price of $12.87 and a two-hundred day moving average price of $13.84. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $18.95.
Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. On average, equities research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
View Our Latest Stock Report on INBX
Inhibrx Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Articles
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
